Announcing a new article publication for BIO Integration journal. The pyrimidine analog 5-flurouracil (5-FU) is effective against solid tumors. However, the half-life of intravenously administered ...

Calcipotriol plus 5-FU immunotherapy activates Th2 immunity, releasing IL-24 cytokines to suppress skin cancer development in patients with actinic keratosis. The combination therapy significantly ...

A new study uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first to activate specific components of the ...

The FDA highlights increased toxicity risks in patients with DPD deficiency when using Xeloda and 5-FU, urging genetic testing before treatment. DPD deficiency leads to severe side effects from ...